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Abstract
Background: The diffusion of health technologies from translational research to reimbursement depends on several
factors included the results of health economic analysis. Recent research identified several flaws in health economic
concepts. Additionally, the heterogeneous viewpoints of participating stakeholders are rarely systematically addressed
in current decision-making. Multi-criteria Decision Analysis (MCDA) provides an opportunity to tackle these issues. The
objective of this study was to review applications of MCDA methods in decisions addressing the trade-off between
costs and benefits.
Methods: Using basic steps of the PRISMA guidelines, a systematic review of the healthcare literature was performed
to identify original research articles from January 1990 to April 2014. Medline, PubMed, Springer Link and specific
journals were searched. Using predefined categories, bibliographic records were systematically extracted regarding the
type of policy applications, MCDA methodology, criteria used and their definitions.
Results: 22 studies were included in the analysis. 15 studies (68 %) used direct MCDA approaches and seven studies
(32 %) used preference elicitation approaches. Four studies (19 %) focused on technologies in the early innovation
process. The majority (18 studies - 81 %) examined reimbursement decisions. Decision criteria used in studies were
obtained from the literature research and context-specific studies, expert opinions, and group discussions. The number
of criteria ranged between three up to 15. The most frequently used criteria were health outcomes (73 %), disease
impact (59 %), and implementation of the intervention (40 %). Economic criteria included cost-effectiveness criteria
(14 studies, 64 %), and total costs/budget impact of an intervention (eight studies, 36 %). The process of including
economic aspects is very different among studies. Some studies directly compare costs with other criteria while
some include economic consideration in a second step.
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Conclusions: In early innovation processes, MCDA can provide information about stakeholder preferences as well
as evidence needs in further development. However, only a minority of these studies include economic features due to
the limited evidence. The most important economic criterion cost-effectiveness should not be included from a technical
perspective as it is already a composite of costs and benefit. There is a significant lack of consensus in methodology
employed by the various studies which highlights the need for guidance on application of MCDA at specific phases of
an innovation.
Keywords: Multi-criteria decision analysis, Decision-making, Health economics, Innovation planning, Stakeholder
involvement
Background
The market for health services and products is is distinct
from other markets in many different ways. The demand
for health services and products is largely decoupled
from prices and customer preferences. Importantly, re-
imbursement decisions of public health care regulate
access and usage of new health technologies [1]. Conse-
quently, these decisions are the bottle neck for medical
innovation in many countries with both economic and
social implications [2, 3].
Currently, health policy decision-making in many coun-
tries is based on health economic concepts. Simultaneously,
manufacturers increasingly use health economic tools [4–8]
to assess investment decisions in the development process
of medical technologies. The rationale behind these
concepts is to compare the costs and the medical benefit
of medical technologies. The most prominent Quality
Adjusted Life Years (QALY) concept provides an esti-
mate to relate the gain in quality of life and life years
versus the associated costs of the medical technology.
The advantage of a single estimate is to compare benefit
and costs of different technologies across different thera-
peutic areas as shown by the large number of published
studies based on QALYs. QALYs are widely used by HTA
agencies, academia and industry because it is assumed as
an objective measure to compare technologies.
Nevertheless, several studies identified flaws in major
features of the QALY concept [9, 10]. A recent survey on
medical utility disapproved the theoretical assumptions of
QALY due to inconsistent preferences [11]. In practical
application, different utility assessment methods to assess
quality of life result in different QALY estimates [12, 13].
For decision-making, Richardson pointed out that the pub-
lic would strongly disagree with the only use of QALY to al-
locate health resources [14]. A reason for this disagreement
is that the benefit of health technologies is so diverse. Other
aspects can confound the simple trade-off in QALYs. Apart
from costs and medical benefit, many other aspects e.g.
severity of disease affect the decision about medical tech-
nologies. Additionally, stakeholders have different perspec-
tives on the diverse benefits of medical innovation [10]. As
health technologies are getting more and more complex,
the understanding of stakeholders on the value of these
technologies diverges further [15]. Such issues question
the methodological basis of trade-offs in current health
policy decision-making.
Decision tools that can systematically integrate costs and
benefits of medical innovations from multiple perspectives
would therefore benefit all stakeholder including patients,
payers and the industry. Multi-criteria decision analysis
(MCDA) offers an opportunity to address this trade-off.
In 1976, Keeney and Raiffa define MCDA as “an extension
of decision theory that covers any decision with multiple
objectives [16].” Belton and Steward describe MCDA as “an
umbrella term to describe a collection of formal approaches
which seek to take explicit account of multiple criteria in
helping individuals or groups explore decisions that matter”
[17]. As outlined by these definitions, MCDA can describe
a broad range of methods. The common key aspects are
the separation of a decision problem into different mutually
independent criteria, the quantification of these criteria
and the final aggregation to a value estimate. For medical
innovation, MCDA can take different stakeholders’ prefer-
ences into account by separating the considerations on the
importance of decision criteria, the evaluation of the per-
formance of health interventions and the evidence on
which such evaluation is based [18].
The objective of this study is to review applications of
MCDA in decisions addressing the trade-off between costs
and benefits, within the development phase and market
access of health technologies. By providing an overview of
published MCDA applications, this study informs poten-
tial users how MCDA can support decision problems in
different decision environments, thus tackling an import-




The objective and the search strategy were established
by using the MIP Scheme. This scheme consists of the
parameters methodology, issues and participants (Meth-
odology =MCDA, Issues = Research, development and
reimbursement decisions, Participants =Manufacturers,
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hospital manager, health care provider, health policy
makers) [19]. MIP is suitable for our research question
because health economic MCDA studies are based on
multiple interventions, outcomes, participants, and set-
tings [20]. The search strategy was performed using basic
steps of the PRISMA Guidelines (see PRISMA checklist in
additional file 2) [21].
Information sources and search
Medline, PubMed, Springer Link and specific journals,
which deal about health economic decision-making, Value
in Health, Health Affairs, Medical Decision Making,
Patient, Cost Effectiveness and Resource Allocation and
Pharmacoeconomics were searched from January 1990 to
April 2014 [22]. According to the MIP Scheme, specific
keywords focused on the methodology to keep the search
as sensitive as possible. Issues and participants were
included in the study selection process (Table 1). Accord-
ingly, the following search terms were used: “MCDA”,
“multi-criteria decision analysis” as well as certain meth-
odologies: “direct weighting”, “balance sheets”, “the even
swap method”, “ordinal methods”, “goal programming”,
“multi attribute utility analysis and the “analytic hierarchy
process”, “AHP”, “ANP”, “Discrete Choice Experiment”
and “Conjoint Analysis”. The keywords were combined
and adapted to each database. Additional articles were
found in the references and citations of the retrieved
articles.
Study selection
The title and abstract of all articles identified by the
database searches were reviewed. Articles meeting initial
inclusion criteria (Table 1) were retrieved and examined
more closely in collaboration with a second researcher
(CKR) until consensus was reached. If both researchers
did not agree, a third researcher was involved (CNI). In
agreement with the objectives of this study, reviewing
applications of MCDA methods in decisions addressing
the trade-off between costs and health benefit, only studies
in which the MCDA process included economic aspects
were included. The quality of research papers was eval-
uated by checking for an adequate description of the
theoretical framework, background, and methodology [23].
Research articles meeting inclusion criteria were appraised
for methodological quality. The studies were required to be
described comprehensively with clear description of the
methods used, criteria selection, weighting, and scoring.
Data collection process and data items
Each study was described in the data extraction form to
highlight heterogeneity between studies. Firstly, information
about the decision context was analyzed. This includes in-
formation about participating stakeholders and the decision
problem. Secondly, the methodology and thirdly, the deci-
sion criteria were extracted, as shown in Table 2. The meth-
odological approach of Guindo et al. was adapted to assess
the included criteria. Criteria were clustered in several
subgroups and quantitative measures were provided [24].
Criteria used in the Analytic Hierarchy Process (AHP) are
hierarchically structured. Therefore, only the main cri-
teria of the hierarchy were counted and sorted into
the subgroups. The data extraction form was tested on
a sample of studies before full data extraction began.
Synthesis of results
After completing the data extraction, a narrative synthe-
sis was compiled according to the objective regarding
the decision context and applied MCDA methodologies.
For the decision context, study characteristics were re-
ported regarding the countries of origin, intervention
characteristics, the level of decision-making, stakeholder
involvement, the level of innovation and evidence charac-
teristics. A descriptive analysis of decision criteria was per-
formed separated into benefit criteria and cost criteria. To
provide a technical overview, the applied methodologies
were systematically decomposed to identify weighting and
scoring techniques. Additionally, stakeholder feedback on
the methodology was reported.
Results
Literature search
2142 papers were retrieved (Fig. 1) and 1974 were ex-
cluded because they were duplicates or not focused on
MCDA or health care. Of the remaining 166 articles, 61
articles were selected for review by two authors (PWA,
CKR) following the criteria in Table 1. Finally, 22 papers
were selected for the literature synthesis [25–46]. The
reasons for exclusions are outlined in Fig. 1.
Table 1 Study selection criteria
No Category Criteria
1 Year of release 1990- April 2014
2 Kinds of
interventions
All kinds of medical interventions and
technologies (no diseases)
3 Innovation process Investment decision, prioritization of new
technologies, HTA, reimbursement
4 Criteria Studies including costs, economic analysis
(should go beyond safety analysis to solve
trade-off between costs and health)
5 MCDA Methodology Original research about MCDA
6 Active stakeholder
involvement
Manufacturers, hospital manager, health care




8 Language English, German
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Terms used in articles
Health outcomes and
benefits of interventions
12 16 Health effects [26], health gain (with 4 sub criteria: life expectancy, quality of life, burden of
treatment, prevalence) [34], improvement of efficacy/effectiveness [36, 37, 39, 40],
improvement of safety & tolerability [36, 37, 39, 40], improvement of patient reported
outcome [36, 37, 39, 40], health benefit [43] , effectiveness [30, 38, 41, 42, 45, 46], patient
comfort [30], safety [30, 33, 46], health-related quality of life [31, 41], complications during
surgery [31], program outcome [32],
Type of health benefit 4 9 Individual health benefits [25, 27, 46], public benefits [29], public health interest [36, 37, 39,
40], type of medical service [36, 37, 39, 40, 42]
Impact of the disease
targeted by intervention
10 13 Severity of disease [25–28, 35–37, 39, 40, 45], number of potential beneficiaries [25, 27, 28],
size of population affected by disease [36, 37, 39, 40, 45], age of target group [25–28, 35],
socioeconomic group [35], equity benefit [43], target groups of interventions [42], gender of
target groups [42], eligible population [44], distribution of benefits [44]
Therapeutic context of
intervention
4 5 Clinical guidelines [36, 37, 39, 40], comparative interventions limitations [36, 37, 39, 40], need
[41], prevention [41]
Economic Impact 12 22 Costs [30, 31, 33], poverty reduction [25–28], cost-effectiveness [25–28, 35–37, 39, 40, 46],
total budget impact to health system [26, 36–40, 43, 45], costs of care [34], marketability
[29], Impact on other spending [36, 37, 39, 40], program infrastructure [32], program outcome
[32], Incremental cost-effectiveness [44, 45], affordability [44, 46]
Quality and uncertainty of
evidence
5 8 Adherence to requirements of decision making body [36], completeness and consistency of
reporting evidence [36, 37, 39, 40], relevance and validity of evidence [36, 37, 39, 40], quality
of evidence [42, 43, 46], certainty [44]
Implementation complexity
of intervention
10 9 Technology applicability [29], system capacity and appropriate use of intervention [37, 40],
technical feasibility [38], practical feasibility [38], information follow-up in time [38], clinical
factors [33], biomedical engineering [33] , process [32, 41], variation in practice [45], technical
complexity [46]
Priorities, fairness and ethics 11 7 Utility [37, 40], efficiency [37, 40], fairness [37, 40], ‘X-factors’ [43], ethical acceptability [38]
access and equity [41], priorities [41], equity/ethical and social implication [45], geographical
coverage [46], accessibility [46]
Overall context 10 7 Stakeholder pressure [37, 40] , political context [37, 40], ‘X-factors’ [43], impact on heath
education [38], Impact on future decisions [39], relationship with pathology providers [39],
impact on screening intervals [39], patient expectation [39], program infrastructure [32],
acceptability [46]
Articles screened n = 1324
Remaining articles 
screened by abstract      
n = 166
Remaining full-text articles 
reviewed again n = 61
22  included articles
Excluded n = 41:
22 only used indirect methods to elicit 
preferences. 
12 did not include economic considerations 
(criteria). 
4 did not assess interventions, only diseases 
2 did not include stakeholders into the MCDA 
process
1 was available only as conference abstract
Articles excluded because of different focus (not 
priority setting) n = 83 
Review articles because not contained original 
research n = 22
Articles excluded because their thematic 
focus was not on MCDA or on health care:    
n = 1156
Articles identified by 
searches n = 2142
Duplicates excluded: n = 818
Other studies identified
n = 2
Fig. 1 Literature selection flow diagram
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Decision context of the MCDA studies
Countries
Table 3 provides descriptive statistics on the included
studies. The 22 studies are from 12 countries, mostly
high- and middle-income (14 studies): Netherlands (4),
Korea (2), Canada (3), UK (2), US (1), France (1), Israel
(1), South Africa (1) and Thailand (2). The four other
studies were from low-income countries: Ghana (2), Nepal
(1) and Ivory Coast (1). Most of the evidence originates
from countries where cost-effectiveness approaches are
already in use as part of funding allocation. These countries
include developed countries like the Netherlands [47] and
Canada [36, 37, 40], where policy-makers already consider
multiple criteria, but also developing countries like Ghana,
where several DCE studies were reported [26, 28]. Studies
about early innovation are all from high-income countries
because the innovators are located there [29–31, 34].
Interventions
The examined MCDA studies assessed a broad range of
medical interventions at different stages of innovation.
These include medical devices (neonatal ventilators,
breast cancer screening technology), drugs (growth hor-
mone, tramadol) and different service programs (breast
cancer screening and treatment, prevention programs,
surgical treatment lung health, liquid-based cytology for
cervical cancer screening, free vaccination service, and
HIV interventions). Some MCDA studies only assessed
one or a few interventions, whereas other studies rank
up to 56 interventions.
Level of decision-making
The studies were conducted at different levels of decision-
making. Two studies applied MCDA for decision-making
on an international level. The majority of 14 studies exam-
ined decision-making on a national level. Three studies
assessed regional decision problems and one study was
conducted in a hospital setting. Two further studies
assessed the development of new products on the level
of manufacturers. Eight studies resulted in implementa-
tion: an official committee considered the MCDA results
in their final decisions. Other studies were conducted in
an explorative manner.
Stakeholders
In terms of stakeholder involvement, Fig. 2 illustrates that
health policy decision-makers were the most strongly in-
volved groups in 16 studies (73 %). Patient involvement
was rare (3 studies, 14 %).
Table 3 Descriptive statistics of included studies
Article Year Country Type of HTA Methodology
Baeten [25] 2010 International (Netherlands, US, UK) Mainstream DCE
Baltussen [26] 2005 Ghana Mainstream DCE
Baltussen [27] 2007 Nepal Mainstream DCE
Bots [34] 1995 The Netherlands Very early SMART (simple attribute rating technique)
Cho [29] 2000 Korea Very early AHP
Diaby [35] 2011 Ivory Coast Mainstream DCE
Goetghebeur [36] 2012 Canada Mainstream Direct weighting, on 5-point scale
Goetghebeur [37] 2010 Canada Mainstream Direct weighting, on 5-point scale
Golan [43] 2012 Israel Mainstream PAPRIKA (Potentially All Pairwise RanKing of all possible Alternatives)
Hilgerink [30] 2011 The Netherlands Early AHP
Hummel [31] 2012 The Netherlands Early AHP
Jehu- Appiah [28] 2008 Ghana Mainstream DCE
Le Gale [38] 1990 France Mainstream Direct weighing and outranking (ELECTRE 1S Model)
Miot [39] 2011 South Africa Mainstream Direct weighting, on 5-point scale
Marsh [44] 2012 UK Mainstream DCE
Shin [32] 2008 South Korea Mainstream AHP
Sloane [33] 2003 US Mainstream AHP
Tony [40] 2010 Canada Mainstream Direct weighting, on 5-point scale
Venhorst [46] 2014 Netherlands Mainstream Direct weighting
Wilson [41] 2006 UK Mainstream Weighted benefit score (WBS)
Youngkong [42] 2011 Thailand Mainstream DCE with deliberation process
Youngkong [45] 2012 Thailand Mainstream Direct weighting with consideration of DCE results
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Level of innovation
This review divided the medical product development
into three levels adapted from Izjerman et al. [7]. Ac-
cordingly, very early HTA is applied on the stage of
basic research. Early HTA covers the stage of translational
research whereas main stream HTA addresses clinical re-
search and market access. Two studies focused on the very
early HTA and the question of which kind of technology
should be supported [29, 34]. Two studies examined the
development and specifications of a certain innovation
(early HTA) [30, 31]. Three of those four studies used an
AHP. The majority of 17 studies examined fully developed
technologies on the level of market access and reimburse-
ment decision (Main stream HTA).
Evidence
The reviewed studies used evidence from different sources.
Table 4 groups them into literature reviews, expert opin-
ions, data obtained from health care system/decision-mak-
ing bodies/manufactures and health economic modeling.
One study used fictitious data [41]. Another study did not
state the underlying evidence [45]. There were large differ-
ences in the level of analysis performed on the evidence.
Most studies did not describe a systematic approach for
reviewing the evidence. Only studies based on the EVIDEM
(Evidence Based Decision Making) framework, which
requires providing synthesized evidence for each decision
criterion, developed a full HTA report made of 14 to 69
references including evaluation of the quality of the evi-
dence. The earlier the MCDA was conducted, the more
expert opinions were included.
Decision criteria
The surveyed studies obtained MCDA decision criteria
from literature research and context-specific studies, ex-
perts in the field, and group discussions with stakeholders.
Some studies used these methods simultaneously. The
selection of criteria depended on the country-specific
decision context, the diffusion level, and the intervention
type. The number of criteria ranged between three and 15,
up to 25 if sub-criteria of AHP were counted [32]. An ana-
lysis of all criteria is summarized in Table 2.
Benefit criteria
The most frequently used criteria described health out-
comes, disease impact and implementation of the interven-
tion. Twelve different criteria measuring health outcomes
and benefits were used in 16 studies (73 %). The impact of
the targeted disease was used by 13 studies (59 %) in ten
different terms. Implementation complexity of intervention
and the type of health benefit were included in eight studies
(41 %).
Cost criteria
As a study selection criteria (defined in Table 1), economic
criteria were used in all included studies. The number of
economic criteria in the assessed studies ranged between
one and three. These criteria included cost-effectiveness (14
studies, 64 %), and total costs/budget impact of an inter-
vention (eight studies, 36 %). There is a widespread hetero-
geneity among the process of including economic criteria.
Four studies considered budget impact and impact on other
spending simultaneously to cost-effectiveness [36, 37,
39, 40]. Economic considerations in different criteria can









People "involved in health care“ 
Public represantives
Number of studies
Fig. 2 Stakeholder involvement
Table 4 Evidence used by studies




Number of studies 14 [25–28, 30–32, 35–37, 39, 40, 42, 44] 10 [26–29, 31–34, 38, 46] 7 [30, 33–35, 38, 39, 43] 2 [31, 44]
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overlap in certain MCDA models. The criterion “cost-ef-
fectiveness” covered the costs of a technology whereas the
criterion “age of target group” included economic consider-
ations regarding the working part of society [27]. An AHP
study included costs in several sub criteria like “Investment
resources for infrastructure”, “governmental budget” and
“economical satisfaction” [32] Four studies considered the
budget impact of an intervention in a second step after
conducting the MCDA [35, 41, 42, 45]. Diaby [35] assessed
cost-effectiveness in a first step. In a second step, budget
impact analysis was used to define reimbursement thresh-
old per patients until the financial threshold is exhausted.
In another study, costs were included by calculating costs
per point in a second step after weighting [41]. In a DCE
study, cost-effectiveness was added into the deliberative
process after the DCE [42]. Another DCE study assessed ef-
fectiveness and economic impact of household expendi-
tures in the first assessment step, value for money (ICER)
and budget impact in the second assessment step [45].
In early innovation studies, the perspective on eco-
nomic considerations was different due to the absence
of economic evidence. Two studies describing an AHP
considered costs in several sub-criteria [29, 32]. Costs
were a main criterion divided into investment in mate-
rials and treatment costs [31]. Costs were one of four
criteria with the sub criteria: scan duration, manpower,
price and peripheral equipment. However, the authors
suggest that cost should be used as a main criterion
without sub-criteria because of several overlaps in the
hierarchical structure [30]. Bots et. al calculated changes
in the cost of care to determine cost-effectiveness [34].
Operationalization of MCDA in the examined studies
MCDA consists of several steps including the assign-
ment of criteria weights, the assignment of performance
scores and the derivation of the total scores. Some stud-
ies also conducted a sensitivity analysis or a deliberative
process. The examined studies performed these steps in
various ways and used various quantitative techniques
for scoring and weighting processes.
Weighting
Seven studies conducted a DCE [25–28, 35, 42, 44]. In
DCE studies, participations had to choose their preferred
intervention from sets of hypothetical scenarios. These
interventions are described by different criteria over a
range of levels. Finally, critria levels weights are calculated.
All other studies used MCDA approach that allows
participants to directly assess the criteria. Within this
group, the AHP was most prevalent (five studies) [29–33].
Participants directly compare certain criteria via trade-offs
on a scale from one to nine. Weights can be calculated via
the right eigenvector.
Six studies were based on a direct weighting approach
[36, 37, 39, 40, 45, 46]. Five studies applied direct weighting
on a one to five scale [36, 37, 39, 40, 46]. One study
considered the results of a DCE in a deliberative process.
As result, six criteria received equal weights [45]. One
study applied the SMART (simple attribute rating tech-
nique) approach by using direct weights with a scale from
0 to100 [34].
Another study used the outranking approaches of
ELECTRE (ELimination and Choice Expressing Reality) in
combination with direct weighting. Direct weighting was
performed for five criteria on a 5-point scale, whereas two
criteria (costs and effectiveness) directly included into the
outranking model [38]. In the study using PAPRIKA (Po-
tentially All Pairwise RanKing of all possible Alternatives)
participants did trade-offs between hypothetical tech-
nologies. Afterwards, a software program (1000minds)
calculates weights for each criterion and level [43]. An-
other study applied weighted benefit scores (WBS) per-
formed the weighting exercise by allocating 100 points
among criteria [41].
Scoring
Weighting in DCE studies was performed by using com-
posite league tables whereas one study explicity added a
deliberative discussion about the result [42]. One DCE
study obtained combined weights and scores as utilitly
scores from a deicison model [44]. Again, AHP studies
applied trade-off rating as described above to obtain
scores. Two studies about early HTA calculated scores
from expert opinions [30] and decision trees [31].
The SMART study used a scale from one to five to
score the evidence [34]. The process was similar y in
another study. Six criteria were scored on a scale of one to
five. Two further criteria were considered as numerical
measures in the final discussion [45]. The four studies
based on the EVIDEM methodology applied direct weight-
ing on a scale from one to four [36, 37, 39, 40]. Scoring
was performed on a scale from zero to two in another
study [46]. For the outranking study, experts’ view on
criteria performance guided the outranking process
(ELECTRE 1S) [38]. The performance was directly scored
on a scale from one to ten in another study [41]. The finals
scores were combined with the costs of options, which re-
sulted in a cost/score ratio. One study stated that the first
author judged the performance levels of the assessed tech-
nologies [43].
Stakeholder feedback on methodology
Stakeholder feedback on the MCDA approach was de-
scribed in 12 studies. One study reported that the
hierarchical structure of AHP seemed too complex to
participants. The high number of evaluated alternatives
made selection even more difficult [29]. The contribution
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of disease specific decision criteria is limited if several in-
terventions for the same disease are assessed [25]. Scoring
exercises were difficult in several studies. The number of
criteria levels needs to be sufficient to represent the real
world [48]. In DCE studies, scoring of criteria with two
levels was sometimes not sufficient. However, adding
more levels would have rendered the discrete choices for
respondents more complex [26, 28, 35, 42].
Discussion
The objective of this study was to review applications of
MCDA methods in decisions addressing the trade-off
between costs and benefits. This review identified im-
portant points relating to implementation of MCDA
approaches.
Methodological shortcomings
There seems to be remarkable lack of consistency in
methodology employed by the various studies that under-
took the MCDA. There was no reasonable process to
make clear why different authors decided to use a certain
methodology. The selection of criteria was more system-
atic but still very different across studies. This resulted in
different numbers and sort of criteria in the examined
studies. Additionally, the scaling of performance scores
raises questions about the methodological validity of these
scales.
In contrast to these shortcomings, the stakeholder
feedback on MCDA highlights the potential value of the
methodology for decision-making. Therefore, we de-
veloped some recommendations for the technical imple-
mentation of MCDA in decision-making. Determinants
of quality were identified regarding the technical aspects of
decision criteria, the scaling of criteria to measure perform-
ance, the weighting method and the underlying evidence.
Defining decision criteria
MCDA can bridge criteria and views that are challenging
to compare, as shown in the specific bioethical context
[49]. Choosing and clustering the right criteria requires
active and direct involvement of stakeholders to avoid
irrelevant or overlapping criteria [45]. The decision cri-
teria should be technically robust regarding potential
overlaps [37]. Every criterion should focus on a single
aspect of the decision to avoid double-counting [50].
Double counting means that the same effect impacts
more than one criterion in the performance matrix. For
example, even though cost-effectiveness was one of six
decision criteria in a study, the criterion “age of target
group” included economic considerations regarding the
working part of society [27]. The implicit consideration
of economics in different criteria can bias the results.
For health policy decision-making, another important
criterion for double counting is the severity of disease.
This criterion can impact several other criteria e.g. econom-
ics, effectiveness, ethics. Therefore, the explicit structuring
of criteria is important. Checking for independent pref-
erences can support the detection of double-counting
effects. A deliberative process can increase the legitimacy
of MCDA criteria selection [42, 51].
Issues on economic criteria
Few studies have suggested the use of separate criteria
describing costs and medical effects instead of the mixed
criterion cost-effectiveness [36, 37]. This makes decision
criteria more transparent and understandable e.g. absolute
costs of an intervention as an easy understandable measure.
Still, cost-effectiveness is the most important economic
criterion in the examined studies which shows a lack of
awareness regarding double counting. Several studies
used more than one economic criterion indicating that
the absolute costs of an intervention should be com-
pared to the impact on the available budget.
The inclusion of economic aspects in decision-making
by MCDA can be very different. Most studies compared
economic criteria with other criteria in one step. In
contrast, some studies considered economic criteria like
budget impact in a second step. This procedure can feed a
deliberative process [42, 45] or a mathematical model to
calculate the reimbursement threshold [35, 41].
In early innovation studies, economic parameters were
simple due to the absence of health economic evidence.
For example, economics for the prospective usage of
photoacoustic imaging for breast cancer diagnosis was
assessed by the criteria “price”, “manpower”, “scan time”
and “peripheral equipment” [30]. In contrast, a study about
new surgery in adolescent idiopathic scoliosis included cost
parameters into a decision tree model to estimate total
costs [31]. This raises the question whether health eco-
nomic analysis should be performed in early innovation
by taking uncertainty into account or to assess only
those simple parameters.
Scaling of criteria
A well-defined scale for every decision criterion should
represent the performance of the assessed alternatives.
Doing so, judgments on well-defined scales are propor-
tional and consistent with the increase in real world
performance. Constructing different levels of performance
for decision parameter is not a trivial task [35]. The
discriminatory power of MCDA can be decreased if
the scaling system and thresholds are not inadequately
constructed [45]. Most of the assessed studies used
rating scales with five or less categories. However, psycho-
logical research showed that scales with more categories
(i.e. 10, 101) support users in expressing their feelings. In
contrast, rating scales with only a few categories support
quick ratings. For most situations, rating scales with seven,
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nine or ten categories are most appropriate taking all
pro and cons into account [52]. Scaling of criteria should
take reliability, discriminatory power and preferences of
participants into account. A sensitivity analysis can
help to determine the uncertainty from scaling effects
e.g. whether more scaling levels contribute to a more exact
result [35, 41]. This can be used to iteratively improve the
MCDA model.
According to the value function approach, direct rating
of the decision criteria by participants can improve the
awareness in decision-making [34, 36, 37, 39, 40]. This ap-
proach reflects the need for explicit statements about the
importance of criteria. Doing so, the importance of criteria
needs definitions among different dimensions [53]. Firstly,
direct weighting provides a relationship between the im-
portance of two criteria (e.g. value of criterion A = 2 vs.
value of criterion B = 4). Secondly, trade-off weights be-
tween criteria need to be compared taking the ranges on
the criteria scales into account. This is covered by the
scoring exercise which is required of any MCDA approach
that was assessed in this review. Thirdly, the starting point
for assessing value trade-offs needs consideration, in par-
ticular if preferences are not linear. A linear relationship
between performance measure and scale is not always ap-
propriate even if measures are constructed in a linear way
[7]. To cover all three dimensions of importance, MCDA
methods like PROMETHEE (Preference Ranking Organ-
isation Method for Enrichment Evaluation) enables the
clear definition of preference functions [54].
Selection of MCDA method
The selection of the MCDA method can affect the uncer-
tainty of decision-making. Different MCDA approaches
vary in structuring the decision problem (i.e. criteria
selection, weighting, scoring, and calculating). This var-
iety causes structural uncertainty [55]. Each MCDA
method has particular advantages for specific phases of
the innovation process [29, 34]. For example, methods
like DCE are very efficient at the beginning of technology
development as they show the conscious and unconscious
preferences of stakeholders. If evidence around technolo-
gies is generated, direct methods can be used for decision
problems about reimbursement [39]. Uncertainty around
evidence can lead to wrong decisions such as reimburse-
ment of an ineffective therapy. An advantage of MCDA is
that a structured decision framework can make this uncer-
tainty more visible within the structure. The evidence and
comments of the stakeholders, involved in the studies,
suggest that direct rating methods can better handle this
uncertainty due to a better understanding of the method-
ologies [29, 35, 42]. Additionally, preference elicitation
techniques cannot support larger numbers of criteria and
scaling levels [25, 28, 35, 42, 44] which again increases the
uncertainty within the MCDA structure. The combination
of different MCDA methods for different parts of the
decision, like criteria weights from DCE and evidence
scores from AHP can improve the decision analysis [25].
Combining different approaches requires assessing the
transferability of the stepwise results. Handling of MCDA
approaches may vary across stakeholder groups [29, 37].
For instance, applying MCDA can be challenging for lay-
people and patients [42, 45]. The evidence suggests that
the cognitive burden of direct weighting methods is lower
in comparison to AHP and DCE [29, 35, 42]. Pragmatic
MCDA means to provide simple and flexible approaches
which are easy to understand by users with little experi-
ence. Doing so, the needs of decision-makers should be
carefully balanced with the resource requirements as well
as the theoretical requirements of certain MCDA method-
ologies. Feasibility and flexibility are important aspects to
ensure acceptability of these approaches [36, 37, 39, 40].
Stakeholder involvement
Awareness about the selection of decision criteria, their
importance [56] and the decision perspective are critical
parts of MCDA from an ethical viewpoint. Stakeholders
have to reflect on their own priorities and rationale to
elucidate their decision-making. Patient involvement was
limited and reported in only 14 % (3 studies), although
they represent the ultimate decision makers on final ac-
ceptance of a healthcare intervention. Inhalable insulin
is an example for innovation failure because of missing
user acceptance in the final phase of the innovation
process [57]. A consistent mix of stakeholders across all
stages of innovation can ensure that all important needs
are addressed. The separation of weighting and scoring
by different stakeholders can result in disagreement [34].
Still, combining many stakeholder perspectives helps to
identify and possibly resolve differences across perspectives.
An essential aspect is to identify the “right” representative-
ness of a certain stakeholder group [45] as well as the
involvement of the “right” stakeholder group. Indeed,
the question, which perspective (their own or another e.g.
society) participants should take into account, is not trivial
[37]. Daniel’s ethical framework of “accountability for rea-
sonableness “ is a widely-agreed rationale regarding fair
decision-making [58]. According to this framework, reim-
bursement decisions should be based on reasons and cri-
teria which reflect society’s values [59]. However, the
consensus of experts does not guarantee that choices are
representative of a societal viewpoint [38, 44]. MCDA
approaches can help make these issues more explicit
and thus provide some methodological basis to feed the
ongoing debate in society about reimbursement decisions.
Evidence needs
Incomplete evidence for the assessed alternatives increases
uncertainty around decisions. Pragmatic MCDA bridging
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HTA methodology with MCDA principles can help clarify
these issues in a systematic manner [36, 37, 39, 40]. Still,
missing data and a time-consuming workload make exist-
ing approaches insufficient [45]. In contrast to mainstream
HTA, the evidence in the development of a technology
is even more based on expert opinion or adaption of evi-
dence from other technologies [29–31, 34]. Most reviewed
studies related to early innovation lack economic consid-
erations because of missing evidence. Finally, missing
evidence can put new technologies at disadvantage in
prioritization decisions [44]. Expert judgments could
replace clinical evidence but the selection of experts can
affect the results [31]. Evidence can also be obtained by
early health economic modeling [31, 44]. There is the
potential for synergies between evidence generation and
MCDA. All MCDA require the involvement of stake-
holder groups to some extent. Different stakeholder
groups can participate in the MCDA decision process
and thus improve the communication of their prefer-
ences and perspectives in a systematic way [18, 60].
Values and preferences of stakeholders are essential to
integrate different decision criteria and to come up
with a decision. For example, AHP supports consensus
finding in groups by calculating an inconsistency ratio
after the scoring exercise. This can be the basis for a
deliberative discussion to refine ratings. In terms of
pragmatic MCDA, stakeholder can contribute to the
selection of decision criteria and the selection of MCDA
techniques to evaluate these criteria. Simultaneously, ex-
perts and stakeholders can support the evidence search
and synthesis, the validation of health economic models,
as well as the MCDA process. Such combination can
contributes to a transparent analytic process and results in
a more comprehensive understanding of the technology in
every phase of innovation. MCDA can facilitate an early
dialogue between manufacturers, regulators and HTA
agencies about evidence needs. This collaboration can
help patients by faster access to treatments as well as
manufacturers for more efficient development of new
technologies.
Limitations of this study
This study should be considered in light of its limitations.
We only included studies that used economic criteria, a
component that was missing in a significant part of the
literature. As there is no clear definition of MCDA, we
only included studies which mentioned MCDA or a
certain described MCDA method. However, other studies
may use MCDA methods without explicitly stating it. The
results reported in the indexed literature could be systemat-
ically different from those presented in the grey literature
such as government reports and white papers [61]. Further
research should focus on how MCDA can contribute to an
efficient innovation process as well as the dynamics of
changing conditions regarding new evidence and its impact
on decision-making. Development of guidelines on the
choice of a particular approach to use at specific phases
of the innovation process would provide value for fur-
ther development in the field. The comparability and
the usefulness of the final MCDA outputs also requires
some further research. Baltussen suggest using the final
result of an MCDA as recommendation, not as formal
list of priorities (60). Another line of research is identi-
fying the implementation and administrative workloads
of MCDA in comparison to existing approaches, and
the overall benefit in decision-making.
Conclusions
This study reveals that MCDA facilitates the trade-off
between costs and benefit in different decision settings
but cannot replace the reflection required for good de-
cisions. MCDA can however increase the transparency,
quality and consistency of decisions. In early innovation,
MCDA can provide information about stakeholder prefer-
ences as well as evidence needs for further development.
Such approaches increase the efficiency of the R&D process
and facilitate access to most beneficial innovations. For
HTA, MCDA allows a more nuanced analysis in different
settings and different countries by explicitly structuring de-
cision criteria and providing a methodological framework
for decision-makers to address the conflict between costs
and medical benefit. Further research is needed to define
guidelines about the conditions of MCDA at specific phases
of an innovation. These should address the appropriateness
of certain MCDA methods, the robustness of models
regarding potential criteria overlaps, performance scales
and opportunities for operationalization. Scaling of criteria’s
performance, like severity of disease, needs careful con-
siderations particularly regarding a sufficient discriminatory
power. MCDA supports understanding the rationale
behind decision-making processes in complex health care
investments, and the constraints of sustainability, effi-
ciency and equity that healthcare systems are facing.
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